i-SEP - the alternative to allogeneic blood transfusions

i-SEP is a Medtech based in Nantes (Upper Brittany, France) focusing on IntraOperative Cell Salvage (IOCS) or Autotransfusion and Patient Blood Management (PBM).

i-SEP has developed and markets a patented innovative technology for the separation of blood components.

Technology

i-SEP markets a new generation of IntraOperative Cell Salvage technology (IOCS) for use in hemorrhagic or high-risk hemorrhagic surgery, capable of recovering not only red blood cells but also the patient’s platelets.

Events & news

Keep up to date with what’s going at i-Sep

i-SEP 1 month ago

i-SEP innovates to combat blood shortages - Present at the CHU x HealthTech Connexion Day , the Nantes MedTech i-SEP presented its latest innovation: an intraoperative auto-transfusion system. Objective? To offer an alternative to blood transfusions from banks during surgical procedures and thus, overcome increasingly frequent shortages.

i-SEP 2 months ago

🚀 We attended the CHU HealthTech Connexion Day #3 at the Grand Palais in Lille! For the past three years, this annual event, organized by the France Biotech association in partnership with the Conference of CHRU General Directors, has been fostering collaborations between university hospitals (CHUs) and HealthTech entrepreneurs. This year, 1,080 participants joined this edition, rich in exchanges and innovations. Highlights of the day: 👉 Guillaume Laurent, i-SEP's Commercial & Marketing Director, spoke during the workshop "From innovative purchasing processes to tailor-made hospital systems: what continuum fosters breakthrough innovation?" This engaging session explored the challenges and drivers of innovation in the healthcare sector alongside Julien Moiroux, Camille Gladieux, Denies Fanette, Benoit DERVAUX, Eric Ermenault, Louis Potel, and Vincent Vercamer. 👉 We also gave an exclusive interview to ON HEALTH, a media platform dedicated to health innovation. Stay tuned to discover our contribution! 📲 A big thank you to everyone who stopped by to learn more about our same™ technology! Our solution addresses a critical public health challenge. By enabling hemorrhagic patients to recover their own red blood cells and platelets, i-SEP provides a significant patient benefit while reducing costs for the healthcare system. In the context of blood supply constraints, this innovative solution represents a major breakthrough in transfusion strategy. 📆 Save the date: Join us on January 24, 25, and 26, 2025, in Los Angeles for the Society of Thoracic Surgeons Conference!

i-SEP 2 months ago

🚀 An important step in deploying our solution across Europe: our first publication introduces a predictive model assessing the budgetary and organizational impact (OBIM) of gradually replacing intraoperative autotransfusion systems in French hospitals. Developed in partnership with RWEALITY and the pharmacy team at the Georges Pompidou European Hospital in Paris, this model anticipates the shift from traditional cell centrifugation, which only preserves red blood cells, to our innovative same™ device. Using tangential filtration, same™ recovers and cleanses the patient’s blood, preserving both platelets and red blood cells, leading to significant cost and efficiency benefits. 🩸In a study of 600 cardiothoracic surgery patients, using same™ resulted in a 45% reduction in red blood cell transfusions. Platelet use decreased by 60% for moderate bleeding and by 90% for severe bleeding, yielding annual savings of €44,601 from the first year, with cumulative savings of €535,206 over five years as the device’s market share grows to 100%. This model offers hospitals a clear, precise view of the expected medico-economic benefits. By quantifying the cost savings and efficiency gains, it supports decision-making for healthcare centers looking to optimize both patient outcomes and resource management.

i-SEP 3 months ago

🩸Cutting-Edge Innovation : How same™ is redefining blood transfusion 🔊 During our recent interview on Télénantes, we shared an update on the rollout of our same™ technology across Europe. Based in Nantes, we are proud to see how our innovation in autotransfusion for cardiac surgery is transforming medical practices in several European countries. 💡 What makes us unique? i-SEP’s device is the first and only Intra Operative Cell Salvage device capable to wash and recover both red blood cells and platelets during surgery. With same™, we not only reduce reliance on blood donations but also allow patients to receive their own blood cells, significantly minimizing the risk of post-operative complications. 🌍 A global impact We work closely with hospitals in France and internationally to make every surgical procedure safer by optimizing the use of vital resources like blood. Every drop counts, and our mission is to improve healthcare for all through innovative technologies. 🎥 This interview on Télénantes was the perfect opportunity to show how i-SEP is shaping the future of medicine. We strongly believe that innovation can not only improve outcomes but also save lives !

Expertise

Autotransfusion, the alternative to
allogenic transfusions